

EC Regulation 1907/2006 Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).

REACH Enforcement Regulations 2008

The regulations require all 'substances', which includes all metals, to be registered under REACH. It is important, however, to note that REACH Regulations distinguish between 'substances' and 'preparations' (which are covered by REACH) and 'articles' (which are not governed by REACH and do not require registration).

Our standard semi-finished products in aluminium, aluminium alloys, stainless steel and copper alloys such as sheet, plate, tube, bar and extrusions, are all classed as 'articles' and do not need to be registered. Billets, blooms, concast slabs and machined ingots are all also classed as 'articles' and do not need to be registered. However, certain types of ingots such as 'as cast' ingots, rolling ingots and ingots produced for extrusion processes, are classed as 'preparations' and would, therefore, need to be registered.

For the reasons stated, we can confirm that products supplied to you from our standard range are classified as 'articles' and, therefore, do not need to be registered under REACH.

A copy of the production diagrams for aluminium and stainless steel is available on request, to help clarify the definitions of 'substances', 'preparations' and 'articles.'

Due diligence has been carried out on our current supplier base to establish that 'substances' and 'preparations' which require registration under REACH have been registered or confirm the absence of such chemicals. For this reason, as far as reasonably practicable, we can confirm that majority of our standard semi-finished products detailed above, don't contain any of the chemicals listed in the current Candidate List of Substances of Very High Concern (SVHC) 23rd January 2024 with the exception of the declaration below:

Additionally, where a grade of material is ordered by a customer where the British, European or International Standard covering the grade requires a deliberate addition of one or more of the substances in order to comply with the standard/grade requirements. In this case, the material will contain a value of each substance in line with the standard requirements:

We declare that some Aluminium & Copper/Brass articles that we sell have the chemical substances, indicated in Attachment XIV of the Reach Regulation as amended on 23/01/2024, present in quantities above 0.1% are:

Substance: Lead

CAS/EINICS: CAS 7439-92-1 / EINICS 231-100-4

Date of inclusion: 27-06-2018

Hazard: Toxic for reproduction Cat. 1A

H360FD - May damage fertility. May damage the unborn child

H362 - May cause harm to breast-fed children

The "Candidate list" of SVHC substances is periodically updated by ECHA and is accessible on: <https://echa.europa.eu/candidate-list-table>

It is possible that you may purchase other products or metal types from us that are outside of our normal stock range. In these circumstances, we would need to check with the producer that these specific products do not contain any of the listed Substances of Very High Concern and we will advise you accordingly.

We trust that this information clarifies our position regarding compliance with the REACH Regulations. If you have any questions or want to check on any specific product that you are unsure about, please contact us.


This Policy will be updated on amendments to the legislation and as a minimum annually.

Please note that this policy specifically excludes: All Plastics and All Composite Panels.

METAL PROCESSING - SHOWN FOR ALUMINIUM PRODUCTS AS EXAMPLE

The example of aluminium processing is included to show the transition point in the processing of bauxite to final aluminium products. It should be noted that the processing of other metals (for example iron / steel) may show different transition points. The following figure shows the different processing stages and the respective status of the raw material.

PLEASE SEE ATTACHED FACT SHEET ON ALUMINIUM AND HEALTH ISSUED 9TH FEBRUARY 2018 BY THE ALUMINIUM REACH CONSORTIUM AND INTERNATIONAL ALUMINIUM INSTITUTE.



Illustrative example of the general transition point from mineral to final aluminium article.

The transition point from preparation to article is set between rolling ingots and sheets, extrusion ingots and extrusion profiles and aluminium alloy and alloy cast pieces.

Similar raw material type in the form of metal and alloy semi-finished products as coil and profile are: bars, blanks (e.g. cut, machined, pressed, etc), coil (coated and uncoated), extrusion profiles, films and filaments, foil and ribbons, forgings, plate, pipe and tube (cast, seamless and welded), pipe and tube fittings, sintered semi-finished and final products, sheet and strip (coated and uncoated), stampings, wire rod and wire (coated and uncoated).

CONTACT

Address: (incorporated in the USA)
Tel: +44 (0)1371 811 642
Email: info@aerometalsalliance.com

REVISION HISTORY

Datasheet Updated 01 March 2024

DISCLAIMER

This Data is indicative only and as such is not to be relied upon in place of the full specification. In particular, mechanical property requirements vary widely with temper, product and product dimensions. All information is based on our present knowledge and is given in good faith. No liability will be accepted by the Company in respect of any action taken by any third party in reliance thereon.

Please note that the 'Datasheet Update' date shown above is no guarantee of accuracy or whether the datasheet is up to date.

The information provided in this datasheet has been drawn from various recognised sources, including EN Standards, recognised industry references (printed & online) and manufacturers' data. No guarantee is given that the information is from the latest issue of those sources or about the accuracy of those sources.

Material supplied by the Company may vary significantly from this data, but will conform to all relevant and applicable standards.

As the products detailed may be used for a wide variety of purposes and as the Company has no control over their use; the Company specifically excludes all conditions or warranties expressed or implied by statute or otherwise as to dimensions, properties and/or fitness for any particular purpose, whether expressed or implied.

Advice given by the Company to any third party is given for that party's assistance only and without liability on the part of the Company. All transactions are subject to the Company's current Conditions of Sale. The extent of the Company's liabilities to any customer is clearly set out in those Conditions; a copy of which is available on request.



Updated Fact Sheet on Aluminium and Health

Prepared for:
Aluminium REACH Consortium/International Aluminium
Institute

9 February 2018

Contents

Updated Fact Sheet on Potential Adverse Health Effects from Exposure to Aluminium and Aluminium Compounds 1

Appendix 1. Glossary..... 5

Appendix 2. References..... 6

Updated Fact Sheet on Potential Adverse Health Effects from Exposure to Aluminium and Aluminium Compounds¹

This Fact Sheet is based on a comprehensive assessment of the scientific literature on the potential health effects of aluminium. Over five years have passed since the first Fact Sheet was developed and new information on the potential adverse health effects of aluminum compounds has become available. The Fact Sheet, developed and written by external consultants, has been updated based on the current scientific data.

Introduction

This Fact Sheet provides a comprehensive summary of the current scientific evidence for potential health effects from aluminium (Al), aluminium oxide (Al₂O₃), and aluminium hydroxide (Al(OH)₃) under typical conditions of exposure. The information provided is based on recent reviews of published peer-reviewed studies in which possible adverse **health effects** from exposure to these substances (by workers, **downstream users**, customers and the general public) have been investigated. Definitions for words in **bold font** can be found in the glossary at the end of the Fact Sheet.

About Al, Al₂O₃, and Al(OH)₃^{1,2,3}

Aluminium (chemical symbol: Al) is ubiquitous in the environment and makes up close to 8% of the Earth's crust by weight. Aluminium is light and resistant to corrosion. Bare aluminium metal is highly reactive and its surface is oxidised immediately on contact with air to form an inert coating of aluminium oxide (chemical formula: Al₂O₃). Al₂O₃ is very hard and poorly soluble in water. In its crystalline form, corundum, it is used as an abrasive and refractory material. Aluminium hydroxide (chemical formula: Al(OH)₃) is the main component of bauxite, a naturally occurring mineral that is the primary source in the manufacture of aluminium metal.



How might I be exposed to aluminium?

People can be exposed to aluminium in the following ways:

- ❖ through the air (in dust from soil);
- ❖ through consumption of food (natural sources, food additives, or minor amounts leached from utensils or food packaging);
- ❖ through drinking water (natural sources or small amounts of an aluminium-containing flocculant used in water purification);
- ❖ through the use of some consumer and pharmaceutical products (e.g., anti-perspirants and aluminium-containing antacids); and
- ❖ in the workplace if employed as aluminium welders or in the production or handling of aluminium substances (workplace exposures occur mainly by inhalation).



The solubility of aluminium and aluminium substances in water is an important factor in determining the amount of **aluminium ion** that actually enters the bloodstream, a quantity known as

¹ Revision: January 15, 2018

bioavailability. Aluminium, aluminium oxide and aluminium hydroxide are poorly soluble in water.^{4,5,6} Less than 0.1% of these substances is absorbed while passing through the gastrointestinal tract.^{7,8} Only a small fraction of these substances is absorbed after being inhaled.⁹ The scientific evidence, including a study in humans,¹⁰ also suggests that aluminium and its insoluble compounds have very limited ability to penetrate the skin,¹¹ indicating that the bioavailability of aluminium following dermal exposure is very low.⁸

What does the science say about aluminium and health effects?

Neurological Effects

Dialysis encephalopathy, a degenerative neurological syndrome, was observed in patients on kidney dialysis who had been exposed to very high levels of aluminium in contaminated dialysate and phosphate-binders. Changes in dialysis procedures have now eliminated this problem.¹²

An area of continuing debate is the possible role of aluminium in the development and progression of **Alzheimer's Disease** and possibly other **neurotoxic effects** that may contribute to declines in cognitive function with age.

Based on the available scientific literature, neurotoxic effects are not expected at the levels of aluminium to which the general public is typically exposed.¹³

A recent **guideline study**^{14,15} has demonstrated mild neurological effects in rats exposed to high levels of aluminium. These effects were only observed at aluminium levels a thousand-fold higher than what is typically found in treated drinking water and food.¹⁵

Recent well-conducted studies investigating whether there is a link between aluminium levels in drinking water and Alzheimer's Disease have provided inconclusive results.¹⁶

Considering all sources of evidence related specifically to Alzheimer's Disease, the current **weight of evidence** does not support a primary role for aluminium in causing this condition.¹⁷

The potential role of aluminium in other diseases involving cognitive decline is under active investigation. At present, there is no clear evidence that such effects are caused by aluminium.

Worker exposures to aluminium are controlled by regulatory standards. The weight of evidence, which is strongly influenced by recent occupational studies^{18,19} does not support a neurotoxic **risk** to workers exposed to airborne aluminium, or aluminium oxide and aluminium hydroxide dusts in workplaces which conform to regulatory standards.^{1-3, 20}

Effects on the Lungs

There is currently no evidence for a chemical-specific **respiratory (fibrogenic) effect** due to exposure to aluminium metal powder.^{21,22}

When not appropriately controlled, several airborne substances in pot-rooms may contribute to an irritation effect in the lungs.²³ The evidence points to a role for fluoride-containing substances^{12,24,25,26} or sulphur dioxide.²⁶ The available evidence suggests that aluminium oxide and aluminium hydroxide behave as “**nuisance dusts**” under current controlled occupational exposure conditions.



Results from workplace studies do not demonstrate allergic reactions or lung sensitisation associated with exposure to aluminium compounds.²⁷ The weight of evidence, supported by negative results from animal dermal **sensitisation** studies,^{28,29} does not suggest a **sensitisation potential** for aluminium metal, aluminium oxide, and aluminium hydroxide dusts through inhalation exposure.³⁰

Effects on Fertility

The weight of evidence, including considerations of bioavailability and results from animal studies, does not indicate effects on reproduction.^{1-3,14,15,31,32}

Effects on Infants and the Developing Foetus

The available data, including considerations of bioavailability and negative results from animal studies on soluble aluminium salts, do not support a risk of developmental effects in humans on exposure to aluminium, or aluminium oxide and aluminium hydroxide dusts.^{1-3,12,13,24,31,32}

Cancer

The weight of evidence from human, animal, and *in-vitro* studies does not support a cancer **hazard** in humans associated with exposure to insoluble aluminium metal, aluminium oxide, or aluminium hydroxide by the oral, inhalation, or dermal routes.^{1-3, 21,33,34}

Although the process of “Aluminium Production” has been classified by IARC^{35,36} as Group 1 (Carcinogenic to Humans), this does not imply that aluminium *per se* is the responsible agent. The evidence supports a role for known **carcinogens**, such as polycyclic aromatic hydrocarbons (PAHs)³⁷ in the workplace, rather than a role for aluminium in this effect.^{13,33,38}

The weight of evidence from several epidemiological studies does not support an association between breast cancer and aluminium-containing antiperspirants.^{12,13,29,40}

The weight of evidence, including considerations of bioavailability and negative results from recent **guideline studies**,⁴¹ also does not support a **mutagenic or genotoxic** hazard from human exposure to aluminium, or aluminium oxide and aluminium hydroxide dusts by the oral and inhalation routes.^{1-3, 12,13}

Other Effects

Aluminium is present in the human diet. For adults, the daily intake of aluminium has been estimated at about 2.5-13.5 mg (0.035 – 0.19 mg per kilogram body weight per day for 70 kg adults) and can be much higher (500 mg or more; 7.14 mg per kilogram body weight or more for 70 kg adults) in individuals taking antacids containing aluminium hydroxide.⁴² Normal dietary levels of intake of aluminium are not associated with acute or long-term adverse health effects.^{13,33}

Case reports of sensitisation by aluminium following exposure of the skin are rare.^{43,44} A recent guideline study in animals exposed to aluminium hydroxide was negative,⁴⁵ as was an industry-sponsored study in which aluminium oxide was investigated.⁴⁶ The weight of evidence suggests limited sensitisation potential for aluminium metal, aluminium oxide, and aluminium hydroxide dusts following dermal exposure.^{1-3,13,33,47}

The Hazard Classification of the Target Aluminium Substances

Aluminium metal, aluminium oxide and aluminium hydroxide are not classified for any hazard class according to Regulation (European Commission) No 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures and the United Nations' Globally Harmonised System of Classification and Labelling of Chemicals (GHS).¹⁻³

Further Research

Although the potential health effects of aluminium have been subject to extensive scientific evaluation, further research in certain areas is warranted. Further data on the **pharmacokinetics** of aluminium is needed. Potential interactions between aluminium and other metals such as iron, copper, and zinc should also be investigated.

Overall Summary

Aluminium is the most abundant metallic element on Earth. It is present in the human diet at moderate levels, less than 15 mg being ingested daily. Aluminium metal is used as a structural material in the construction, automotive, and aircraft industries, in the production of metal alloys, in the electrical industry, in cooking utensils, and in food packaging. Aluminium compounds are used as coagulants with beneficial effects in water treatment, as antacids, antiperspirants, and food additives.

A number of different organisations have suggested dietary intake limits for aluminium. A recent decision by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) established a provisional tolerable weekly intake (PTWI) of 2 mg aluminium per kilogram body weight or 0.29 mg aluminium per kilogram body weight per day. The PTWI applies to all aluminium compounds in food, including food additives.⁴⁹

This fact sheet provides a summary of the evidence for potential health effects from aluminium (Al), aluminium oxide (Al₂O₃), and aluminium hydroxide (Al(OH)₃) under exposure conditions typically found in the workplace, in the general environment, and in the diet. At current exposure levels, based on the available data, there is no evidence that these compounds are associated with adverse health outcomes in the general population.

Appendix 1. Glossary

Alzheimer's Disease: Alzheimer's Disease (AD) is a progressive, degenerative disease of the brain, which causes thinking and memory to become impaired. It is the most common form of dementia. Dementia is a syndrome consisting of a number of symptoms that include loss of memory.

(For further information see: <http://www.alzheimer.ca/english/disease/intro.htm>).

Bioavailability: The quantity or fraction of a chemical that actually enters the blood stream.

Carcinogen: An agent that increases the risk of cancer in humans.

Dialysis Encephalopathy: A degenerative neurological syndrome, characterized by the gradual loss of motor, speech, and cognitive functions.

Downstream users: Companies or individuals who use a substance, either on its own or in a mixture, in their industrial or professional activities

(For further information see: <https://echa.europa.eu/regulations/reach/downstream-users/about-downstream-users/who-is-a-downstream-user>).

Fibrogenic Effect: An adverse health effect associated with the development of fibrous tissue in the lungs, resulting in a loss of the tissue's ability to transfer oxygen into the bloodstream.

Gastrointestinal Irritation: A condition associated with irritation and inflammation of the stomach and intestines. The main symptoms are gastric and/or abdominal pain, mild to moderate diarrhoea, and nausea, with or without vomiting.

Genotoxicity: The capacity of a chemical or an agent to alter genetic material (DNA) in living cells.

Guideline Study: A study conducted according to an internationally agreed upon testing method, such as the OECD Test Guideline established by the Organization for Economic Cooperation and Development (OECD).

Hazard: "The intrinsic property of the agent that makes it capable of causing adverse effects to occur in humans or the environment, under specific conditions of exposure." (For future information see: http://www.hc-sc.gc.ca/ahc-asc/alt_formats/hpfb-dgpsa/pdf/pubs/risk-risques-eng.pdf).

Metal Ion: A metal is an element, compound, or alloy characterized by a capacity to conduct electricity and heat. Metal ions (specifically cations - positively charged ions) are formed by electron loss.

Mutagenicity: The capacity of a chemical or an agent to induce or increase the frequency of mutation in an organism.

Neurotoxic Effect: An adverse effect on nervous system cells and tissues associated with pathological changes in the structure or function of the nervous system.

Nuisance Dusts: Dust particles which are poorly soluble in water and have low sensitization potential and toxicity (other than by inflammation or the mechanism of "lung overload").

Pharmacokinetics: The quantitative assessment of the movement of chemicals within the body following exposure.

Risk: "A measure of both the harm to human health that results from being exposed to a hazardous agent, together with the likelihood that the harm will occur." (For future information see: http://www.hc-sc.gc.ca/ahc-asc/alt_formats/hpfb-dgpsa/pdf/pubs/risk-risques-eng.pdf).

Skin Sensitisation: Skin sensitisation (allergic contact dermatitis) is an immune response to an environmental agent. In humans, sensitization responses may be characterised by pruritis (itching), erythema (redness), oedema (swelling), and blisters.

Sensitisation Potential: The ability to cause an allergic reaction that results in the development of hypersensitivity (a condition in which the allergic response to a second or later exposure is greater than the response to the first exposure to the substance) to an environmental agent.

Appendix 2. References

1. Aluminium REACH Consortium. (2014). Chemical Safety Report. Substance Name: Al metal - 7429-90-5. Aluminium REACH Consortium. 2014-05-14 CSR-PI-5.4.1.
2. Aluminium REACH Consortium. (2014). Chemical Safety Report. Substance Name: Al oxide - 1344-28-1. Aluminium REACH Consortium. 2014-05-14 CSR-PI-5.4.1.
3. Aluminium REACH Consortium. (2014). Chemical Safety Report. Substance Name: Al hydroxide - 21645-51-2. Aluminium REACH Consortium. 2014-05-15 CSR-PI-5.4.1.
4. Harlan Laboratories Ltd, UK. (2010). Al Metal. Determination of water solubility. Project No.: 2962/0001. January 4, 2010. A study conducted at the request of the Aluminium REACH Consortium.
5. Harlan Laboratories Ltd, UK. (2010). Al Oxide. Determination of water solubility. Project No.: 2962/0002. January 4, 2010. A study conducted at the request of the Aluminium REACH Consortium.
6. Harlan Laboratories Ltd, UK. (2010). Al Hydroxide. Determination of water solubility. Project No.: 2962/0003. UK. January 4, 2010. A study conducted at the request of the Aluminium REACH Consortium.
7. Priest, N.D., Newton, D., Talbot, B., McAughey, J., Day, P., Fifield, K. (1998). Industry-sponsored studies on the biokinetics and bioavailability of aluminium in man. In T.V. O'Donnell, N.D. Priest (Eds.), *Health in the aluminium industry: managing health in the aluminium industry*. London, UK: Middlesex University Press.
8. Priest, N.D. (1997). The Harwell Series Human Volunteer Studies on the Biokinetics and Bioavailability of Aluminium. A compilation of reports. AEA Report No. AEA-EE-0206. United Kingdom. 1997.
9. Priest, N.D. (2004). The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. *Journal of Environmental Monitoring*. 6: 375-403.
10. Flarend, R., Bin, T., Elmore, D., & Hem, S. L. (2001). A preliminary study of the dermal absorption of aluminium from antiperspirants using aluminium-26. *Food & Chemical Toxicology*. 39: 163-168.
11. Lansdown AB. (1973). Production of epidermal damage in mammalian skins by some simple aluminium compounds. *British Journal of Dermatology*. 89: 67-76.
12. Krewski, D., Yokel, R.A., Nieboer, E., Borchelt, D., Cohen, J., Harry, J., Kacew, S., Lindsay, J., Mahfouz, A.M., Rondeau, V. (2007). Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. *Journal of Toxicology & Environmental Health, Part B: Critical Reviews*. 10: 1-269.
13. Willhite CC, Karyakina NA, Yokel RA, Yenugadhati N, Wisniewski TM, Arnold IMFF, Momoli F, Krewski D. (2014). Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. *Critical Reviews in Toxicology*. 44: 1-80.
14. ToxTest TEH-113. (2010). One-Year Developmental and Chronic Neurotoxicity Study of Aluminium Citrate in Rats. ToxTest Final Report. Alberta Research Council Inc, Canada. Project No. TEH -113. April 20, 2010.
15. Poirier, J., Semple, H., Davies, J., Lapointe, R., Dziwenka, M., Hiltz, M., Mujibi, D. (2011). Double-blind, vehicle-controlled randomized twelve-month neurodevelopmental toxicity study of common aluminum salts in the rat. *Neuroscience*. 193: 338-362.
16. Rondeau, V., Commenges, D., Jacqmin-Gadda, H., Dartigues, J.F. (2000). Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study. *American Journal of Epidemiology*. 152: 59-66.
17. Lidsky, T.I. (2014). Is the Aluminum Hypothesis dead? *Journal of Occupational and Environmental Medicine*. 56 (Suppl.): S73-9.
18. Kiesswetter, E., Schäper, M., Buchta, M., Schaller, K. H., Rossbach, B., Kraus, T., Letzel, S. (2009). Longitudinal study on potential neurotoxic effects of aluminium: II. Assessment of exposure and neurobehavioral performance of Al welders in the automobile industry over 4 years. *International Archives of Occupational & Environmental Health*. 82:1191-1210.
19. Kiesswetter, E., Schäper, M., Buchta, M., Schaller, K. H., Rossbach, B., Scherhag, H., Zschiesche, W., Letzel, S. (2007). Longitudinal study on potential neurotoxic effects of aluminium: I. Assessment of exposure and neurobehavioural performance of Al welders in the train and truck construction industry over 4 years. *International Archives of Occupational and Environmental Health*. 81: 41-67.
20. Wesdock, J.C. and Arnold, I.M.F. (2014). Occupational and environmental health in the aluminum industry. *Journal of Occupational and Environmental Medicine*. 56 (Suppl 5): S5-S11.
21. Donoghue, A.M., Frisch, N., Olney, D. (2014). Bauxite mining and alumina refining: process description and occupational health risks. *Journal of Occupational and Environmental Medicine*. 56: S12-17.
22. Dennekamp, M., de Klerk, N.H., Reid, A., Abramson, M.J., Cui, J., Del Monaco, A., Fritschi, L., Benke, G.P., Sim, M.R., Musk, A.W. (2015). Longitudinal analysis of respiratory outcomes among bauxite exposed workers in Western Australia. *American Journal of Industrial Medicine*. 58: 897-904.
23. Søyseth, V., Henneberger, P.K., Einvik, G., Virji, M.A., Bakke, B., Kongerud, J. (2016). Annual decline in forced expiratory volume is steeper in aluminum potroom workers than in workers without exposure to potroom fumes. *American Journal of Industrial Medicine*. 59: 322-329.
24. ATSDR/Agency for Toxic Substances and Disease Registry. (2008). *Toxicological Profile for Aluminum*. September 2008. Atlanta, GA.: US Department of Health & Human Services, Public Health Service.

25. Donoghue, A.M., Frisch, N., Ison, M., Walpole, G., Capil, R., Curl, C., Di Corleto, R., Hanna, B., Robson, R., Viljoen, D. (2011). Occupational asthma in the aluminum smelters of Australia and New Zealand: 1991–2006. *American Journal of Industrial Medicine*. 54: 224-231.
26. Abramson, M.J., Benke, G.P., Cui, J., de Klerk, N.H., Del Monaco, A., Dennekamp, M., Fritsch, L., Musk, A.W., Sim, M.R. (2010). Is potroom asthma due more to sulphur dioxide than fluoride? An inception cohort study in the Australian aluminium industry. *Occupational and Environmental Medicine*. 67: 679-685.
27. Donoghue, A.M., Frisch, N., Ison, M., Walpole, G., Capil, R., Curl, C., Di Corleto, R., Hanna, B., Robson, R., Viljoen, D. (2011). Occupational asthma in the aluminum smelters of Australia and New Zealand: 1991–2006. *American Journal of Industrial Medicine*. 54: 224-431.
28. Basketter, D.A., Lea, L.J., Cooper, K.J., Ryan, C.A., Gerberick, G.F., Dearman, R.J., Kimber, I. (1999). Identification of metal allergens in the local lymph node assay. *American Journal of Contact Dermatitis*. 10: 207-212.
29. Lab Research Ltd, Hungary. (2010). Aluminium hydroxide: A skin sensitisation study in the guinea pig using the Magnusson and Kligman method. Final Report. Study No.: 09/164-104T, February 03, 2010. A study conducted at the request of the Aluminium REACH Consortium.
30. Kongerud, J., Søyseth, V. (2014). Respiratory disorders in aluminum smelter workers. *Journal of Occupational and Environmental Medicine*. 56: S60–S70.
31. Hirata-Koizumi, M., Fujii, S., Ono, A., Hirose, A., Imai, T., Ogawa, K., Ema, M., Nishikawa, A. (2011a). Evaluation of the reproductive and developmental toxicity of aluminium ammonium sulfate in a two-generation study in rats. *Food and Chemical Toxicology*. 49: 1948-1959.
32. Hirata-Koizumi, M., Fujii, S., Ono, A., Hirose, A., Imai, T., Ogawa, K., Ema, M., Nishikawa, A. (2011b). Two-generation reproductive toxicity study of aluminium sulfate in rats. *Reproductive Toxicology*. 31: 219-230.
33. Willhite, C.C., Tait, V., Karyakina, N.A., Nordheim, E., Arnold, I., Armstrong, V., Momoli, F., Shilnikova, N.S., Yenugadhati, N., Krewski, D. (2018). The REACH process: A case study of metallic aluminium, aluminium oxide and aluminium hydroxide. 143 p. (Submitted to *Neurotoxicology. Special Issue on Aluminium and Health*).
34. Donoghue, A.M., Coffey, P.S. (2014). Health risk assessments for alumina refineries. *Journal of Occupational and Environmental Medicine*. 56: S18-22.
35. IARC/ International Agency for Research on Cancer. (2012). Chemical Agents and Related Occupations. Occupational Exposures during Aluminium Production. IARC monographs on the evaluation of carcinogenic risks to humans. 100F; 215-223 (<http://monographs.iarc.fr/ENG/Monographs/vol100F/>).
36. IARC/ International Agency for Research on Cancer. (2017). List of classifications. IARC monographs on the evaluation of carcinogenic risks to humans. 1-120. (http://monographs.iarc.fr/ENG/Classification/latest_classif.php).
37. Baan, R., Grosse, Y., Straif, K., Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., Coglian, V. WHO International Agency for Research on Cancer Monograph Working Group. (2009). A review of human carcinogens- Part F: chemical agents and related occupations. *The Lancet Oncology*. 10: 1143-1144.
38. Gibbs, G.W., Labrèche, F. (2014). Cancer risks in aluminum reduction plant workers: a review. *Journal of Occupational and Environmental Medicine*. 56: S40-59.
39. Namer, M., Luporsi, E., Gligorov, J., Lokiec, F., & Spielmann, M. (2008). [The use of deodorants/antiperspirants does not constitute a risk factor for breast cancer]. *Bulletin du Cancer*. 95: 871-880.
40. Klotz, K., Weistenhöfer, W., Neff, F., Hartwig, A., van Thriel, C., Drexler, H. (2017). The Health Effects of Aluminum Exposure. *Deutsches Arzteblatt International*. 114: 653-659.
41. Covance Laboratories Ltd. (2010). Aluminium hydroxide: induction of micronuclei in the bone marrow of treated rats. Covance Laboratories Ltd, 2010. Report. Covance Study Number 8221368.
42. IPCS/ International Programme on Chemical Safety. (1997). *Aluminium*. Environmental Health Criteria 194. Geneva: World Health Organization.
43. Kligman, A.M. (1966a). The identification of contact allergens by human assay. III. The maximization test; a procedure for screening and rating contact sensitizers. *The Journal of Investigative Dermatology*. 47: 393-409.
44. Kligman, A.M. (1966b). The identification of contact allergens by human assay. II. Factors influencing the induction and measurement of allergic contact dermatitis. *The Journal of Investigative Dermatology*. 47: 375-392.
45. Lab Research Ltd, Hungary. (2010). Aluminium hydroxide: a skin sensitisation study in the guinea pig using the Magnusson and Kligman method. Final Report. Study No.: 09/164-104T. Lab Research Ltd, Hungary. February 03, 2010. A study conducted at the request of the Aluminium REACH Consortium.
46. Til, HP, and Keizer, AMM. (1977) Sensitization potential of Al oxide. Report No. R 6181. Date: 79-09-18. Study code: 79-0010-DKT. Central Institute for Nutrition and Food Research, Germany.
47. RSI/ Risk Sciences International, Inc. (2010). Hazard Assessment Report. Target Chemical Substances: Aluminium Metal (CAS# 7429-90-5), Aluminium Hydroxide (CAS# 21645-51-2) and Aluminium Oxide (CAS# 1344-28-1). Prepared for Aluminium REACH Consortium. Final Report. October 2010. Ottawa.
48. Benford, D.J., Agudo, A., Baskaran, C., DiNovi, M., Folmer, D., Leblanc, J-C., Renwick, A.G. (2011). Aluminium-containing food additives (addendum). WHO Additives Series 65: Safety Evaluation of Certain Food Additives and Contaminants. Geneva: Food and Agriculture Organization of the United Nations/World Health Organization (For future information see: http://apps.who.int/iris/bitstream/10665/44520/1/9789241660631_eng.pdf).